Relevant bibliographies by topics / Adderare / Journal articles
To see the other types of publications on this topic, follow the link: Adderare.

Journal articles on the topic 'Adderare'

Author: Grafiati
Published: 4 June 2021
Last updated: 18 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Adderare.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

&NA;. "Adderall." Reactions Weekly &NA;, no. 1204 (2008): 5. http://dx.doi.org/10.2165/00128415-200812040-00014.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

&NA;. "Adderall." Reactions Weekly &NA;, no. 1077 (2005): 6. http://dx.doi.org/10.2165/00128415-200510770-00017.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Vanga, Rohini R., Bikram Bal, and Kevin W. Olden. "Adderall Induced Acute Liver Injury: A Rare Case and Review of the Literature." Case Reports in Gastrointestinal Medicine 2013 (2013): 1–3. http://dx.doi.org/10.1155/2013/902892.

Full text
Abstract:
Adderall (dextroamphetamine/amphetamine) is a widely prescribed medicine for the treatment of attention-deficit/hyperactivity disorder (ADHD) and is considered safe with due precautions. Use of prescribed Adderall without intention to overdose as a cause of acute liver injury is extremely rare, and to our knowledge no cases have been reported in the English literature. Amphetamine is an ingredient of recreational drugs such as Ecstacy and is known to cause hepatotoxicity. We describe here the case of a 55-year-old woman who developed acute liver failure during the treatment of ADHD with Adderall. She presented to the emergency room with worsening abdominal pain, malaise, and jaundice requiring hospitalization. She had a past history of partial hepatic resection secondary to metastasis from colon cancer which was under remission at the time of presentation. She recovered after intensive monitoring and conservative management. Adderall should be used carefully in individuals with underlying liver conditions.
APA, Harvard, Vancouver, ISO, and other styles
4

Stowe, Cindy D., Stephanie F. Gardner, Charles C. Gist, Eldon G. Schulz, and Thomas G. Wells. "24-Hour Ambulatory Blood Pressure Monitoring in Male Children Receiving Stimulant Therapy." Annals of Pharmacotherapy 36, no. 7-8 (2002): 1142–49. http://dx.doi.org/10.1345/aph.1a367.

Full text
Abstract:
OBJECTIVE: To determine whether cardiac indices are altered as assessed by 24-hour ambulatory blood pressure monitoring (ABPM) in male children receiving either chronic methylphenidate or dextroamphetamine/levoamphetamine (Adderall) therapy. METHODS: Boys 7–11 years old who were receiving methylphenidate or Adderall for a minimum of 2 months were asked to participate. Subjects wore ambulatory blood pressure monitors for 24-hour periods both off and on stimulant therapy. RESULTS: Subjects (n = 17; 8 methylphenidate, 9 Adderall) were well matched. Systolic blood pressure (SBP), diastolic blood pressure (DBP), and heart rate differed between off and on stimulant therapy (p < 0.05). DBP load calculated from ABPM reference data was increased significantly (9.0% ± 5.6% on and 4.8% ± 4.5% off therapy; p < 0.05) while subjects were taking Adderall. There was a trend toward a greater elevation in blood pressure load during awake hours and a more pronounced decrease during the asleep hours for periods on compared with off-stimulant therapy. This trend resulted in significant (p < 0.05) nocturnal dipping on-stimulant phases compared with off-stimulant therapy for both SBP and DBP (Adderall) and SBP (methylphenidate). Two subjects (1 Adderall, 1 methylphenidate) met the criteria to be considered hypertensive based both on mean awake and 24-hour blood pressure load assessments during their on-treatment period. One additional subject receiving Adderall therapy met the criteria to be considered hypertensive based on blood pressure load criteria while off therapy only. Positive correlation coefficients (p < 0.05) were found when comparing stimulant dose (mg/kg) with the percent change of mean SBP, DBP, and heart rate between off and on therapy (r = 0.56, 0.61, and 0.58, respectively). CONCLUSIONS: These preliminary data suggest that blood pressure and heart rate appear to be altered in male patients while receiving stimulant therapy for attention-deficit hyperactivity disorder. Blood pressure and heart rate screening and monitoring during stimulant therapy to determine whether alterations become clinically significant is encouraged.
APA, Harvard, Vancouver, ISO, and other styles
5

&NA;. "Adderall interaction." Reactions Weekly &NA;, no. 1174 (2007): 4. http://dx.doi.org/10.2165/00128415-200711740-00012.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

&NA;. "Adderall/methylphenidate." Reactions Weekly &NA;, no. 1177 (2007): 5. http://dx.doi.org/10.2165/00128415-200711770-00008.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Thomas, Stephanie, and Himanshu Upadhyaya. "ADDERALL AND SEIZURES." Journal of the American Academy of Child & Adolescent Psychiatry 41, no. 4 (2002): 365. http://dx.doi.org/10.1097/00004583-200204000-00005.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Rose, Sherrill, Kristi S. Borowski, Wendy M. White, Matthew Hathcock, and Enid Rivera-Chiauzzi. "Adderall and Pregnancy." Obstetrics & Gynecology 131 (May 2018): 39S—40S. http://dx.doi.org/10.1097/01.aog.0000532976.17300.b9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Sikes, Carolyn, Jeffrey G. Stark, Russ McMahen, and Dorothy Engelking. "A Single-Dose, Two-Way Crossover, Open-Label Bioequivalence Study of an Amphetamine Extended-Release Oral Suspension in Healthy Adults." Journal of Attention Disorders 24, no. 3 (2017): 414–19. http://dx.doi.org/10.1177/1087054717743329.

Full text
Abstract:
Objective: The purpose of this study was to compare the pharmacokinetics of a new extended-release amphetamine oral suspension (AMP XR-OS) with a standard extended-release mixed amphetamine salts product, Adderall XR®. Method: In this single-dose, open-label, randomized, two-period, two-treatment crossover study, 42 healthy adult volunteers received 15 mL of AMP XR-OS in one period and a 30 mg Adderall XR capsule in another period (both containing 18.8 mg of amphetamine base) under fasted conditions. Blood samples were analyzed for d- and l-amphetamine concentrations, and pharmacokinetic parameters Cmax, AUC0-5, AUC5-last, and AUCinf were calculated to determine bioequivalence. Safety was monitored throughout the study. Results: The 90% confidence intervals (CIs) for the log-transformed Cmax, AUC0-5, AUC5-last, and AUCinf fell within the accepted 80% to 125% range for establishing bioequivalence for d- and l-amphetamine. The most common adverse events were nausea and decreased appetite. Conclusion: AMP XR-OS is bioequivalent to Adderall XR in healthy adult participants.
APA, Harvard, Vancouver, ISO, and other styles
10

MCGOUGH, JAMES J., JOSEPH BIEDERMAN, LAURENCE L. GREENHILL, et al. "Pharmacokinetics of SLI381 (ADDERALL XR), an Extended-Release Formulation of Adderall." Journal of the American Academy of Child & Adolescent Psychiatry 42, no. 6 (2003): 684–91. http://dx.doi.org/10.1097/01.chi.0000046850.56865.cb.

Full text
APA, Harvard, Vancouver, ISO, and other styles
11

McKeage, Kate, and Lesley J. Scott. "SLI-381 (Adderall XR??)." CNS Drugs 17, no. 9 (2003): 669–75. http://dx.doi.org/10.2165/00023210-200317090-00006.

Full text
APA, Harvard, Vancouver, ISO, and other styles
12

Johnston, Charlotte. "SLI-381 (Adderall XR??)." CNS Drugs 17, no. 9 (2003): 676–77. http://dx.doi.org/10.2165/00023210-200317090-00007.

Full text
APA, Harvard, Vancouver, ISO, and other styles
13

Ambrosini, Paul J. "SLI-381 (Adderall XR??)." CNS Drugs 17, no. 9 (2003): 676–77. http://dx.doi.org/10.2165/00023210-200317090-00008.

Full text
APA, Harvard, Vancouver, ISO, and other styles
14

Diller, Lawrence H. "ADDERALL AND THE FDA." Journal of the American Academy of Child & Adolescent Psychiatry 40, no. 7 (2001): 737. http://dx.doi.org/10.1097/00004583-200107000-00001.

Full text
APA, Harvard, Vancouver, ISO, and other styles
15

Biron, P. "Questions about Adderall XR." Canadian Medical Association Journal 174, no. 9 (2006): 1303–4. http://dx.doi.org/10.1503/cmaj.1060004.

Full text
APA, Harvard, Vancouver, ISO, and other styles
16

Millichap, J. Gordon. "Assessment of Adderall in ADHD." Pediatric Neurology Briefs 12, no. 5 (1998): 40. http://dx.doi.org/10.15844/pedneurbriefs-12-5-14.

Full text
APA, Harvard, Vancouver, ISO, and other styles
17

Splete, Heidi. "Health Canada Reinstates Adderall XR." Clinical Psychiatry News 33, no. 10 (2005): 8. http://dx.doi.org/10.1016/s0270-6644(05)70848-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
18

Fitzgerald, Kevin T., and Alvin C. Bronstein. "Adderall® (Amphetamine-Dextroamphetamine) Toxicity." Topics in Companion Animal Medicine 28, no. 1 (2013): 2–7. http://dx.doi.org/10.1053/j.tcam.2013.03.002.

Full text
APA, Harvard, Vancouver, ISO, and other styles
19

Splete, Heidi. "Health Canada Reinstates Adderall XR." Internal Medicine News 38, no. 21 (2005): 55. http://dx.doi.org/10.1016/s1097-8690(05)72279-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
20

&NA;. "Health Canada Suspends Adderall Sales." Nurse Practitioner 30, no. 6 (2005): 66. http://dx.doi.org/10.1097/00006205-200506000-00024.

Full text
APA, Harvard, Vancouver, ISO, and other styles
21

ALBUCHER, RONALD C., and GEORGE C. CURTIS. "Adderall for Obsessive-Compulsive Disorder." American Journal of Psychiatry 158, no. 5 (2001): 818—a—819. http://dx.doi.org/10.1176/appi.ajp.158.5.818-a.

Full text
APA, Harvard, Vancouver, ISO, and other styles
22

Alsidawi, Said, James Muth, and James Wilkin. "Adderall induced inverted-Takotsubo cardiomyopathy." Catheterization and Cardiovascular Interventions 78, no. 6 (2011): 910–13. http://dx.doi.org/10.1002/ccd.23036.

Full text
APA, Harvard, Vancouver, ISO, and other styles
23

Allen, Shari N. "Adderall XR® and Vyvanse™." Mental Health Clinician 4, no. 1 (2014): 8–10. http://dx.doi.org/10.9740/mhc.n186948.

Full text
Abstract:
Adderall XR® (MAS XR) and Vyvanse™ (LDX) are both schedule II amphetamine-based central nervous system stimulants indicated for the treatment of attention-deficit/hyperactivity disorder. Differences among the two primarily involve dosage form, pharmacokinetic profiles, and abuse potential. MAS XR and LDX are both long-acting stimulants with an approximate duration of action of 10 hours. The long-acting property of LDX is secondary to its prodrug formulation, whereas MAS XR utilizes bead filled capsules that mimic twice daily dosing upon administration. MAS XR is a substrate of CYP 2D6 while LDX does not utilize the cytochrome P450 enzymes for metabolism. There are few efficacy studies that directly compare LDX and MAS XR. There are no head to head abuse liability studies for MAS XR and LDX; however, the prodrug formulation of LDX is proposed to have lower abuse potential.
APA, Harvard, Vancouver, ISO, and other styles
24

MCNAMARA, DAMIAN. "Aczone Gel, 5% and Adderall XR." Pediatric News 39, no. 9 (2005): 45. http://dx.doi.org/10.1016/s0031-398x(05)70588-9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
25

MCNAMARA, DAMIAN. "Aczone Gel 5% and Adderall XR." Family Practice News 35, no. 18 (2005): 31. http://dx.doi.org/10.1016/s0300-7073(05)71747-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
26

Barkley, Russell. "Adderall XR Restored to Canadian Market." Child and Adolescent Psychopharmacology News 10, no. 4 (2005): 10. http://dx.doi.org/10.1521/capn.2005.10.4.10.1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
27

Marks, Donald H. "Cardiomyopathy Due to Ingestion of Adderall." American Journal of Therapeutics 15, no. 3 (2008): 287–89. http://dx.doi.org/10.1097/mjt.0b013e3180ed6291.

Full text
APA, Harvard, Vancouver, ISO, and other styles
28

Horrigan, Joseph P., L. Jarrett Barnhill, and R. Robin Kohli. "ADDERALL, THE ATYPICALS, AND WEIGHT GAIN." Journal of the American Academy of Child & Adolescent Psychiatry 40, no. 6 (2001): 620. http://dx.doi.org/10.1097/00004583-200106000-00004.

Full text
APA, Harvard, Vancouver, ISO, and other styles
29

Forrester, Mathias B. "Adderall Abuse in Texas, 1998–2004." Journal of Toxicology and Environmental Health, Part A 70, no. 7 (2007): 658–64. http://dx.doi.org/10.1080/15287390600974619.

Full text
APA, Harvard, Vancouver, ISO, and other styles
30

Cheng, Christine M., Alejandra Salazar, Mary G. Amato, Bruce L. Lambert, Lynn A. Volk, and Gordon D. Schiff. "Using drug knowledgebase information to distinguish between look-alike-sound-alike drugs." Journal of the American Medical Informatics Association 25, no. 7 (2018): 872–84. http://dx.doi.org/10.1093/jamia/ocy043.

Full text
Abstract:
Abstract Objective To extract drug indications from a commercial drug knowledgebase and determine to what extent drug indications can discriminate between look-alike-sound-alike (LASA) drugs. Methods We extracted drug indications disease concepts from the MedKnowledge Indications module from First Databank Inc. (South San Francisco, CA) and associated them with drugs on the Institute for Safe Medication Practices (ISMP) list of commonly confused drug names. We used high-level concepts (rather than granular concepts) to represent the general indications for each drug. Two pharmacists reviewed each drug’s association with its high-level indications concepts for accuracy and clinical relevance. We compared the high-level indications for each commonly confused drug pair and categorized each pair as having a complete overlap, partial overlap or no overlap in high-level indications. Results Of 278 LASA drug pairs, 165 (59%) had no overlap and 58 (21%) had partial overlap in high-level indications. Fifty-five pairs (20%) had complete overlap in high-level indications; nearly half of these were comprised of drugs with the same active ingredient and route of administration (e.g., Adderall, Adderall XR). Conclusions Drug indications data from a drug knowledgebase can discriminate between many LASA drugs.
APA, Harvard, Vancouver, ISO, and other styles
31

&NA;. "Revised labelling for Adderall XR in Canada." Reactions Weekly &NA;, no. 1068 (2005): 2. http://dx.doi.org/10.2165/00128415-200510680-00001.

Full text
APA, Harvard, Vancouver, ISO, and other styles
32

Gandhi, Pritesh J., Gladys U. Ezeala, Tuonglan T. Luyen, Tran C. Tu, and Maichi T. Tran. "Myocardial infarction in an adolescent taking Adderall." American Journal of Health-System Pharmacy 62, no. 14 (2005): 1494–97. http://dx.doi.org/10.2146/ajhp040220.

Full text
APA, Harvard, Vancouver, ISO, and other styles
33

&NA;. "Revised labelling for Adderall XR in Canada." Inpharma Weekly &NA;, no. 1504 (2005): 20. http://dx.doi.org/10.2165/00128413-200515040-00054.

Full text
APA, Harvard, Vancouver, ISO, and other styles
34

Splete, Heidi. "Adderall XR Gets Indication for Adolescent ADHD." Clinical Psychiatry News 33, no. 8 (2005): 11. http://dx.doi.org/10.1016/s0270-6644(05)70574-9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
35

Brunk, Doug. "Health Canada Suspends Sale of Adderall XR." Internal Medicine News 38, no. 6 (2005): 67. http://dx.doi.org/10.1016/s1097-8690(05)70222-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
36

Sichilima, Tangu, and Michael J. Rieder. "Adderall and cardiovascular risk: A therapeutic dilemma." Paediatrics & Child Health 14, no. 3 (2009): 193–95. http://dx.doi.org/10.1093/pch/14.3.193.

Full text
APA, Harvard, Vancouver, ISO, and other styles
37

Gaudiano, Maria Cristina, Anna Borioni, Eleonora Antoniella, and Luisa Valvo. "Counterfeit Adderall Containing Aceclofenac from Internet Pharmacies." Journal of Forensic Sciences 61, no. 4 (2016): 1126–30. http://dx.doi.org/10.1111/1556-4029.13095.

Full text
APA, Harvard, Vancouver, ISO, and other styles
38

Millichap, J. Gordon. "Ritalin and Adderal Comparison in ADHD." Pediatric Neurology Briefs 13, no. 6 (1999): 44. http://dx.doi.org/10.15844/pedneurbriefs-13-6-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
39

Fegert, J. M., and A. G. Ludolph. "Neue Zweifel an der Psychostimulanzien-Therapie der ADHS." Nervenheilkunde 25, no. 10 (2006): 849–54. http://dx.doi.org/10.1055/s-0038-1626790.

Full text
Abstract:
ZusammenfassungDie Debatte um den therapeutischen Einsatz von Psychostimulanzien bei der Aufmerksamkeitsdefizit-Hyperaktivitätsstörung (ADHS) im Kindes- und Jugendalter und zunehmend auch im Erwachsenenalter reißt auf Grund der ständig steigenden Verordnungszahlen nicht ab. Nachrichten aus Nordamerika führen auch hier zu Lande immer wieder zu Verunsicherungen. 2005 wurde in Kanada die Zulassung für das Amphetaminpräparat Adderall XR® für ein halbes Jahr ausgesetzt, weil in den USA und anderen Ländern unter der Einnahme dieser Substanz ungeklärte Todesfälle bei Kindern aufgetreten waren. Eine kleine Studie in Texas ergab im selben Jahr Hinweise auf genotoxische und somit womöglich mutagene Eigenschaften von Methylphenidat bei Kindern. Im Februar 2006 empfahl eine Expertenkommission der amerikanischen Zulassungsbehörde einen Warnhinweis für Stimulanzienpräparate, eine so genannte „black box warning“. Anlass waren ungeklärte Todesfälle unter der Medikation mit Methylphenidatpräparaten. In diesem Übersichtsartikel sollen dargestellt werden 1) die Unterschiede im Umgang mit Psychostimulanzien in den USA und Deutschland, insbesondere bezogen auf die Zulassung von Präparaten und Prävalenz der Verordnungen; 2) die Datenlage bezüglich der ungeklärten Todesfälle unter dem Amphetaminpräparat Adderall® und verschiedener Metyhlphenidatpräparate 3) welche Implikationen die texanische Studie an 12 Kindern haben könnte, in der zytogenetische Effekte unter der Behandlung mit Methylphenidat gefunden wurden. Festgestellt wird, dass in Deutschland der therapeutische Umgang mit Psychostimulanzien nicht geändert werden muss.
APA, Harvard, Vancouver, ISO, and other styles
40

Nesby, Eunike. "Vilken svensk författare motsvarar Knut Hamsun och Örnulf Tigerstedt?" Nordlit, no. 47 (December 9, 2020): 65–76. http://dx.doi.org/10.7557/13.5632.

Full text
Abstract:
”Vilken svensk författare motsvarar Japans Yukio Mishima, Tysklands Ernst Jünger och Frankrikes Louis-Ferdinand Céline?”, frågar en svensk debattör och forskare i en artikel 2016. Till dessa om än famösa så välkända namn adderar frågeställaren Norges Knut Hamsun respektive Finlands Örnulf Tigerstedt. Med denna fråga som utgångspunkt granskas och prövas i artikeln såväl nazistiska partiledare och nazistanhängare som svenska nationalpoeter. Vilka diktare är att betrakta som nazistiska och vilka har associerats med nazismen på felaktiga grunder? Och var alla nazistiska diktare män? I nutid med yttringar av vad som betecknats som ultranationalism och populism i ytterlighetsrörelser, till sin spets dragna i form av nynazism, är det viktigare än någonsin att göra upp med det nazistiska förflutna och utreda hur nazismen gestaltades i den nazistiska kampdikten, såväl i den svenska som i den nordiska.
APA, Harvard, Vancouver, ISO, and other styles
41

Millichap, J. Gordon. "Randomized, Controlled Study of Adderall XR in ADHD." Pediatric Neurology Briefs 16, no. 8 (2002): 64. http://dx.doi.org/10.15844/pedneurbriefs-16-8-13.

Full text
APA, Harvard, Vancouver, ISO, and other styles
42

Millichap, J. Gordon. "Long-Term Effects of Adderall XR in ADHD." Pediatric Neurology Briefs 19, no. 6 (2005): 48. http://dx.doi.org/10.15844/pedneurbriefs-19-6-10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
43

&NA;. "Health Canada suspends Adderall, US FDA advises caution." Reactions Weekly &NA;, no. 1039 (2005): 2. http://dx.doi.org/10.2165/00128415-200510390-00003.

Full text
APA, Harvard, Vancouver, ISO, and other styles
44

&NA;. "Adderall XR allowed back on the Canadian market." Reactions Weekly &NA;, no. 1067 (2005): 2. http://dx.doi.org/10.2165/00128415-200510670-00002.

Full text
APA, Harvard, Vancouver, ISO, and other styles
45

&NA;. "???Adderall??? for ADHD and hypersomnia in the US." Inpharma Weekly &NA;, no. 1027 (1996): 22. http://dx.doi.org/10.2165/00128413-199610270-00044.

Full text
APA, Harvard, Vancouver, ISO, and other styles
46

&NA;. "Health Canada suspends Adderall, US FDA advises caution." Inpharma Weekly &NA;, no. 1475 (2005): 20. http://dx.doi.org/10.2165/00128413-200514750-00049.

Full text
APA, Harvard, Vancouver, ISO, and other styles
47

&NA;. "Adderall XR allowed back on the Canadian market." Inpharma Weekly &NA;, no. 1503 (2005): 21. http://dx.doi.org/10.2165/00128413-200515030-00053.

Full text
APA, Harvard, Vancouver, ISO, and other styles
48

Flanigan, Jessica. "Adderall for All: A Defense of Pediatric Neuroenhancement." HEC Forum 25, no. 4 (2013): 325–44. http://dx.doi.org/10.1007/s10730-013-9222-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
49

&NA;. "??? but benefits of ???Adderall??? may be longer lasting." Inpharma Weekly &NA;, no. 1185 (1999): 15. http://dx.doi.org/10.2165/00128413-199911850-00028.

Full text
APA, Harvard, Vancouver, ISO, and other styles
50

Innes, Carmen. "???Adderall??? gets all the attention in ADHD studies." Inpharma Weekly &NA;, no. 1195 (1999): 13–14. http://dx.doi.org/10.2165/00128413-199911950-00025.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the bibliographies on the topic 'Adderare' for other source types:
Dissertations / Theses
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography